参考文献

［1］SIEGEL R L，MILLER K D，JEMAL A.Cancer statistics，2020.CA：A Cancer Journal for Clinicians，2020，70（1）：7-30.

［2］CHEN W，ZHENG R，BAADE P D，et al.Cancer statistics in China，2015.CA Cancer J Clin，2016，66（2）：115-132.

［3］PERERA M，PAPA N，CHRISTIDIS D，et al.Sensitivity，Specificity，and Predictors of Positive（68）Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer：A Systematic Review and Meta-analysis.European urology，2016，70（6）：926-937.

［4］EPSTEIN J I，EGEVAD L，AMIN M B，et al.The 2014 International Society of Urological Pathology（ISUP）Consensus Conference on Gleason Grading of Prostatic Carcinoma：Definition of Grading Patterns and Proposal for a New Grading System.Am J Surg Pathol，2016，40（2）：244-252.

［5］KAMRAN S C，DAMICO A V.Radiation Therapy for Prostate Cancer.Hematol Oncol Clin North Am，2020，34（1）：45-69.

［6］LI X M，GAO X S，GUO X M.Using CT imaging to delineate the prostatic apex for radiation treatment planning.Chinese journal of cancer，2010，29（11）：914-922.

［7］QI X，GAO X S，ASAUMI J，et al.Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer：comparison between EORTC prostate cancer radiotherapy guideline，RTOG0815 protocol and actual anatomy.Radiation oncology，2014（9）：288.

［8］SALEMBIER C，VILLEIRS G，DE BARI B，et al.ESTRO ACROP consensus guideline on CT-and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.Radiotherapy and oncology：journal of the European Society for Therapeutic Radiology and Oncology，2018，127（1）：49-61.

［9］ALUWINI S，POS F，SCHIMMEL E，et al.Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer（HYPRO）：late toxicity results from a randomised，non-inferiority，phase 3 trial.The Lancet Oncology，2016，17（4）：464-474.

［10］DEARNALEY D，SYNDIKUS I，MOSSOP H，et al.Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer：5-year outcomes of the randomised，non-inferiority，phase 3 CHHiP trial.The Lancet Oncology，2016，17（8）：1047-1060.

［11］INCROCCI L，WORTEL R C，ALEMAYEHU W G，et al.Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer（HYPRO）：final efficacy results from a randomised，multicentre，open-label，phase 3 trial.The Lancet Oncology，2016，17（8）：1061-1069.

［12］LEE W R，DIGNAM J J，AMIN M B，et al.Randomized Phase Ⅲ Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2016，34（20）：2325-2332.

［13］CATTON C N，LUKKA H，GU C S，et al.Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2017，35（17）：1884-1890.

［14］HOFFMAN K E，VOONG K R，LEVY L B，et al.Randomized Trial of Hypofractionated，Dose-Escalated，Intensity-Modulated Radiation Therapy（IMRT）Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2018，36（29）：2943-2949.

［15］ROYCE T J，LEE D H，KEUM N，et al.Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer：A Meta-analysis of Randomized Noninferiority Trials.Eur Urol Focus，2019，5（4）：577-584.

［16］HOCHT S，AEBERSOLD D M，ALBRECHT C，et al.Hypofractionated radiotherapy for localized prostate cancer.Strahlentherapie und Onkologie：Organ der Deutschen Rontgengesellschaft，2017，193（1）：1-12.

［17］JACKSON W C，SILVA J，HARTMAN H E，et al.Stereotactic Body Radiation Therapy for Localized Prostate Cancer：A Systematic Review and Meta-Analysis of Over 6，000 Patients Treated On Prospective Studies.International journal of radiation oncology，biology，physics，2019，104（4）：778-789.

［18］WIDMARK A，GUNNLAUGSSON A，BECKMAN L，et al.Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer：5-year outcomes of the HYPORT-PC randomised，non-inferiority，phase 3 trial.The Lancet，2019，394：385-395.

［19］BRAND D H，TREE A C，OSTLER P，et al.Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer（PACE-B）：acute toxicity findings from an international，randomised，open-label，phase 3，non-inferiority trial.The Lancet Oncology，2019，20（11）：1531-1543.

［20］IWATA H，ISHIKAWA H，TAKAGI M，et al.Long-term outcomes of proton therapy for prostate cancer in Japan：a multi-institutional survey of the Japanese Radiation Oncology Study Group.Cancer Med，2018，7（3）：677-689.

［21］TRAN A，ZHANG J，WOODS K，et al.Treatment planning comparison of IMPT，VMAT and 4π radiotherapy for prostate cases.Radiation oncology，2017，12（1）：10.

［22］LANDRY G，HUA CH.Current state and future applications of radiological image guidance for particle therapy.Medical physics，2018，45（11）：e1086-e1095.

［23］NABID A，CARRIER N，MARTIN AG，et al.Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer：A Randomized Phase Ⅲ Trial.European urology，2018，74（4）：432-441.

［24］MORRIS W J，TYLDESLEY S，RODDA S，et al.Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy（the ASCENDE-RT Trial）：An Analysis of Survival Endpoints for a Randomized Trial Comparing aLow-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High-and Intermediaterisk Prostate Cancer.International journal of radiation oncology，biology，physics，2017，98（2）：275-285.

［25］RODDA S，TYLDESLEY S，MORRIS WJ，et al.ASCENDE-RT：An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High-and Intermediate-Risk Prostate Cancer.International journal of radiation oncology，biology，physics，2017，98（2）：286-295.

［26］HALL W A，PAULSON E，DAVIS B J，et al.NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.Int J Radiat Oncol Biol Phys，2021，109（1）：174-185.

高献书　亓昕